佐力藥業(300181.SZ):擬使用不超3億元閒置募集資金和不超2億元閒置自有資金進行現金管理
格隆匯3月14日丨佐力藥業(300181.SZ)公佈,公司於2023年3月14日召開了第七屆董事會第十四次(臨時)會議、第七屆監事會第十二次(臨時)會議,分別審議通過了《關於使用部分閒置募集資金和閒置自有資金進行現金管理的議案》,同意公司使用額度不超過人民幣3億元(含本數)的閒置募集資金和不超過人民幣2億元(含本數)的閒置自有資金進行現金管理,現金管理有效期自董事會審議通過之日起12個月內有效,在上述額度及有效期內,資金可以循環滾動使用。此次使用部分閒置募集資金和閒置自有資金進行現金管理事項在董事會決策權限內,無需提交股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.